Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): A propensity score-matched study
Maria Vittoria Dieci(Istituto Oncologico Veneto), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Miglietta(University of Padua), Stefano Angelini, Grazia Maria Vernaci(University of Padua), Giulia Tasca(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Silvia Michieletto(Istituto Oncologico Veneto), Alice Menichetti(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Giovanni Faggioni(Istituto Oncologico Veneto), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Mara Mantiero(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), Elisa Genovesi(University of Padua), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Simona Frezzini(Istituti di Ricovero e Cura a Carattere Scientifico)
Cited by 0
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226